Taurocholic acid (Synonyms: N-Choloyltaurine)

Name: Taurocholic acid
Brand: MedChemExpress
SKU: HY-B1788
Rating: 5.0 (31 reviews)

Cat. No.: HY-B1788 Purity: 99.83%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect.

For research use only. We do not sell to patients.

CAS No. : 81-24-3

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 31 publication(s) in Google Scholar

Other Forms of Taurocholic acid:

Taurocholic acid-d₄ sodium In-stock
Taurocholic acid-d₄ In-stock
Taurocholic acid sodium salt hydrate In-stock
Taurocholic acid sodium In-stock
Taurocholic acid (Standard) In-stock
Taurocholic acid-d₅ Get quote

31 Publications Citing Use of MCE Taurocholic acid

In Vivo Efficacy Study

ELISA

Histological Imaging/Staining

RT-PCR

: Taurocholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb 3:e2411719. [Abstract]; The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.

: Taurocholic acid purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jul;643(8070):192-200.; Taurocholic acid (TCA, 100 μM, 4 h) activated AMPK depending on the cAMP–Epac–MEK pathway in primary hepatocytes.

: Taurocholic acid purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102.; Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced systolic blood pressure in spontaneously hypertensive rats.

: Taurocholic acid purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102.; Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced plasma levels of norepinephrine in spontaneously hypertensive rats.

: Taurocholic acid purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102.; Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced cardiomyocyte dilation (A-B) and fibrosis (C-D) in spontaneously hypertensive rats.

: Taurocholic acid purchased from MedChemExpress. Usage Cited in: Food Funct. 2024 May 7;15(9):5088-5102.; Taurocholic acid (TCA, infused into the PVN at 10 μg per day for 28 days) reduced the average fluorescence intensity of DHE in cardiomyocytes of spontaneously hypertensive rats.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	4.95 μM Compound: 5a, tauro	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
HEK293	IC₅₀	250 μM Compound: Cholate	TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from MRP4-expressing HEK-293 cells TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from MRP4-expressing HEK-293 cells	[PMID: 14643890]
HEK293	IC₅₀	350 μM Compound: Taurocholate	TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from MRP4-expressing HEK-293 cells TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from MRP4-expressing HEK-293 cells	[PMID: 12523936]
HEK293	IC₅₀	40 μM Compound: Taurocholate	TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.4 uM) in membrane vesicles from MRP3-expressing HEK cells TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.4 uM) in membrane vesicles from MRP3-expressing HEK cells	[PMID: 12924948]
HeLa	IC₅₀	5.3 μM Compound: Cholate	TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells	[PMID: 10565843]
Hepatocyte	IC₅₀	6 μM Compound: TCA	Inhibition of [3H]taurocholate uptake in rat hepatocytes Inhibition of [3H]taurocholate uptake in rat hepatocytes	[PMID: 15261266]
Oocyte	IC₅₀	1480 μM Compound: Taurocholate	TP_TRANSPORTER: inhibition of Digoxin uptake in Xenopus laevis oocytes TP_TRANSPORTER: inhibition of Digoxin uptake in Xenopus laevis oocytes	[PMID: 11561088]

In Vitro

Taurocholic acid (100 μM, 24 h) decreases the proportion of CD3+CD8+ T and NK cells in isolated PBMCs from HBeAg-positive CHB patients^[2].
Taurocholic acid (100 μM, 24 h) decreases IFN-α stimulated cytokine and cytotoxic granule levels (IFN-γ, TNF-α, granzyme B) in CD3+CD8+ T and NK cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Taurocholic acid (oral gavage, 100 mg/kg, 2 weeks) sodium promotes HBV replication by reducing the percentage of NK and CD3+CD8+ T cells in C57BL/6 mice with tail vein injection with rAAV8-1.3HBV^[2].
Taurocholic acid (1% in diet, 1 week) sodium prevents hepatic artery ligation (HAL)-induced cholangiocyte damage in rats by upregulation of VEGF-A expression^[3].
Taurocholic acid can be used in animal modeling to create stress-induced gastric injury models and pancreatitis models^[3]^[4]^[5].
Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

1. Induction of stress-induced gastric injury^[3]

Background

Both in humans and experimental animals, Taurocholic acid irritates the gastric mucosa and causes the reverse diffusion of acid through the broken barrier.

Specific Modeling Methods

Rat: Donryu strain rats • male • 230-240 g
Administration: 30-300 mg/kg • p.o • single dose.

Note

After rats have fasted for 24 hours, their pylorus is ligated under ether anesthesia. Fifteen minutes after pylorus ligation, medication is administered to the rats.
The pylorus-ligated rats are then placed in cages with restricted movement.
Subsequently, the cages are immersed in a water bath maintained at 23°C until the water level reaches the xiphoid process of the rats, lasting for 7 hours.
Seven hours later, the animals are sacrificed under ether anesthesia, and the stomach of each animal is removed. The gastric contents are collected through the esophagus and analyzed for volume and acidity.

Modeling Indicators

Molecular Changes: Significant reductions in acidity and pepsin activity were observed, along with an increase in Na⁺ concentration. However, there was no effect on gastric juice volume or K⁺ concentration.

Correlated Product(s): Aspirin (HY-14654)

Opposite Product(s): L-Glutamine (HY-N0390)

2. Induction of Acute Pancreatitis^[4]

Background

Taurocholic acid induced the formation of interstitial edema and caused acinar cell vacuolization in the pancreatic lobules. Taurocholic acid also increased serum amylase and lipase activities. Interstitial edema becomes one of the most important criteria for assessing pancreatic damage in acute pancreatitis^[4].

Specific Modeling Methods

Rat: Wistar • male • weighing 220-240 g
Administration: 1 mL/kg • retrograde infusion into the common pancreaticobiliary duct • at a speed of 0.25 mL/min^[4]
Mice: Balb/c and Wistar • male • weighing 25-30 g and 250-300 g^[5]
Administration: 1 mL/kg • retrograde infusion • perfusion for 8 h^[5]

Note

(1) Before administration, mice were kept at room temperature of 23±1°C and 50-60 % relative humidity with free access to water and chow on a 12-h light/dark cycle. They were allowed to adapt to this environment for 5 days before the experiment, and received no nourishment and free access to water for 12 h preoperatively^[1]^[2].
(2) Pancreatic acinar cells were isolated freshly from Balb/c or C57/BL6J mice using a collagenase IV. Cells were treated under room temperature, and used within 4 hours after isolation^[2].

Modeling Indicators

Histological analysis: Taurocholic acid administration caused the formation of interstitial edema in the pancreas and an increase of pancreas weight. Acinar cell vacuolization was evident in the pancreatic lobules, accompanied by some foci of pancreatic hemorrhage and marked peritoneal ascites. A pyknotic nucleus was in the center of necrotic acinar cell with a bright border. Taurocholic acid administration induced marked oedema, inflammatory cell infiltration and acinar cell necrosis^[1]^[2].
Biochemical Analysis: Taurocholic acid administration increased serum amylase and lipase activities^[1].

Correlated Product(s): Neuronostatin; Flavonoids 1

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice^[2]
Dosage:	100-mg/kg
Administration:	oral gavage, for 2 weeks after tail vein injection with rAAV8-1.3HBV for 6 weeks
Result:	Reduced the percentage of NK and CD3+CD8+ T cells. Increases serum HBsAg, HBeAg, and HBV DNA levels.

Molecular Weight

515.70

Formula

C₂₆H₄₅NO₇S

CAS No.

81-24-3

Appearance

Solid

Color

White to off-white

SMILES

O[C@H](C[C@]1([H])C[C@@H]2O)[C@@]([C@@](C[C@@H]3O)([H])[C@]1(CC2)C)([H])[C@@](CC[C@]4([H])[C@H](C)CCC(NCC[S](=O)(O)=O)=O)([H])[C@@]43C

Structure Classification

Steroids

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (193.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 100 mg/mL (193.91 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9391 mL	9.6956 mL	19.3911 mL
5 mM	0.3878 mL	1.9391 mL	3.8782 mL
10 mM	0.1939 mL	0.9696 mL	1.9391 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (4.85 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.83%

Select Batch:

Data Sheet (286 KB) SDS (393 KB)

COA (249 KB) HNMR (458 KB) RP-HPLC (208 KB) MS (68 KB)

Handling Instructions (2659 KB)

References

[1]. Mooranian A, et al. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv Transl Res. 2015 Oct;5(5):511-22. [Content Brief]

[2]. Xun Z,et al. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function. Cell Mol Immunol. 2021 Feb;18(2):461-471. [Content Brief]

[3]. Glaser S, et al. Taurocholic acid prevents biliary damage induced by hepatic artery ligation in cholestatic rats. Dig Liver Dis. 2010 Oct;42(10):709-17. [Content Brief]

[4]. Mo J, Yang A, et al. Neuronostatin ameliorates sodium taurocholate-induced acute pancreatitis in rats. Dig Dis Sci. 2013 Oct;58(10):2903-7. [Content Brief]

[5]. Du D, Yao L, et al. Protective effects of flavonoids from Coreopsis tinctoria Nutt. on experimental acute pancreatitis via Nrf-2/ARE-mediated antioxidant pathways. J Ethnopharmacol. 2018 Oct 5;224:261-272. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	1.9391 mL	9.6956 mL	19.3911 mL	48.4778 mL
	5 mM	0.3878 mL	1.9391 mL	3.8782 mL	9.6956 mL
	10 mM	0.1939 mL	0.9696 mL	1.9391 mL	4.8478 mL
	15 mM	0.1293 mL	0.6464 mL	1.2927 mL	3.2319 mL
	20 mM	0.0970 mL	0.4848 mL	0.9696 mL	2.4239 mL
	25 mM	0.0776 mL	0.3878 mL	0.7756 mL	1.9391 mL
	30 mM	0.0646 mL	0.3232 mL	0.6464 mL	1.6159 mL
	40 mM	0.0485 mL	0.2424 mL	0.4848 mL	1.2119 mL
	50 mM	0.0388 mL	0.1939 mL	0.3878 mL	0.9696 mL
	60 mM	0.0323 mL	0.1616 mL	0.3232 mL	0.8080 mL
	80 mM	0.0242 mL	0.1212 mL	0.2424 mL	0.6060 mL
	100 mM	0.0194 mL	0.0970 mL	0.1939 mL	0.4848 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Taurocholic acid Related Classifications

Neurological Disease Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Taurocholic acid81-24-3N-CholoyltaurineEndogenous Metabolitehepatic arteryVEGF-A expressionliver cirrhosisImmunoregulationTumor necrosis factor-αInterleukin-1βCD4+/CD8+Inhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Taurocholic acid (Synonyms: N-Choloyltaurine)

Customer Review

Other Forms of Taurocholic acid:

Taurocholic acid Related Antibodies

31 Publications Citing Use of MCE Taurocholic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Taurocholic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Taurocholic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report